View details of this raise on Seedstage

San Diego, CA

Developing precision medicine to address neurodegenerative diseases through innovative drug discovery.

• Innovative Drug Discovery: Origami Therapeutics uses its ORICISION platform to develop small molecule drugs targeting misfolded proteins.
• Focus on Neurodegenerative Diseases: The company is advancing treatments for diseases like Huntington’s, Alzheimer’s, and Parkinson’s.
• Experienced Leadership: Founded by Dr. Beth Hoffman, who has a proven track record in drug discovery and development.
• Lean Operational Model: Origami employs a capital-efficient approach, focusing resources on advancing scientific research.
• Strong Industry Interest: The company has filed multiple patents and is in discussions with major pharmaceutical companies.

Origami Therapeutics is advancing its drug candidate, ORI-003, aimed at treating Huntington’s disease by targeting the root cause of neurodegeneration: misfolded proteins. The company is preparing for IND-enabling safety studies, a crucial step before applying to begin human trials. This approach leverages their proprietary ORICISION platform to develop small molecule drugs that either tag misfolded proteins for destruction or correct their shape, utilizing the body’s own selective autophagy process. Origami’s method aims to prevent, reverse, or slow neurodegenerative diseases by restoring brain health.

Founded by Dr. Beth Hoffman, a veteran biotech executive with a track record of discovering FDA-approved drugs, Origami Therapeutics is focused on neurodegenerative diseases such as Huntington’s, Alzheimer’s, and Parkinson’s. The company employs a lean, capital-efficient model, outsourcing non-core functions and using patient-derived cell models to streamline early testing. With multiple patents filed and strong interest from major pharmaceutical companies, Origami is positioned to expand its platform to address a wide range of neurodegenerative diseases, creating significant value through its innovative approach to drug discovery and development.

Company Info

Origami Therapeutics develops precision medicine targeting neurodegenerative diseases by eliminating misfolded proteins.

Origami Therapeutics focuses on developing precision medicine to address neurodegenerative diseases such as Huntington’s, Alzheimer’s, and Parkinson’s. Utilizing their proprietary ORICISION platform, they aim to create small molecule drugs that target and eliminate misfolded proteins, which are a key factor in these diseases. Their approach involves using patient-derived cells to test drug candidates, enhancing the likelihood of success in clinical trials.

The company’s lead program targets Huntington’s disease, with their drug candidate ORI-003 showing promise in reversing disease symptoms in both human-derived neurons and animal models. Origami’s strategy is to address the root cause of neurodegeneration, offering orally available treatments that penetrate the brain. Their scalable platform has the potential to expand into other neurodegenerative conditions, providing hope for new therapeutic options in a field with significant unmet needs.